MedTrace Logo

Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy

NCT00336557 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1230

Last updated 2013-10-30

No results posted yet for this study

Summary

An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.

Conditions

Interventions

PROCEDURE

NAbs testing

blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Stephen Glenski, PharmD · Teva Neuroscience, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2009-04-30
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00336557 on ClinicalTrials.gov